What is the real cost of bevacizumab for patients with advanced bowel cancer?

Dixon, Lorraine (2010) What is the real cost of bevacizumab for patients with advanced bowel cancer? International Journal of Palliative Nursing, 16 (12). p. 577. doi:10.12968/ijpn.2010.16.12.577

Full text not available from this repository.

Abstract

The author comments on the decision of the National Institute for Health and Clinical Excellence (NICE) of Great Britain not to support the use of bevacizumab for patients with advanced bowel cancer despite evidence indicating that the drug would grant patients with advanced cancer additional weeks of life compared with chemotherapy alone. The author relates the cost of bevacizumab per patient and why NICE found that bevacizumab therapy failed to demonstrate clinical cost effectiveness. She emphasizes the value of palliative care for cancer patients.

Item Type:	Article
Article Type:	Article
Uncontrolled Keywords:	Bowel cancer, drug therapy; bowel cancer, biological therapy
Subjects:	R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RM Therapeutics. Pharmacology
Divisions:	Schools and Research Institutes > School of Health and Social Care
Research Priority Areas:	Society and Learning
Depositing User:	Susan Turner
Date Deposited:	18 Feb 2015 15:49
Last Modified:	27 Jul 2023 15:59
URI:	https://eprints.glos.ac.uk/id/eprint/1384

University Staff: Request a correction | Repository Editors: Update this record